Search PubMed⌕ Search

Biomedical subjects

A Eschalier

Publications and source records attributed to A Eschalier.

147 records · Page 9Linked to original sources

[Vitamin B12, an analgesic vitamin? Critical examination of the literature].

Since 1950 it would seem that in some countries vitamin B12 has been regarded as a painkilling vitamin. Only one of the 94 published clinical trials fails to point to this conclusion, but none of these trials meets current methodological requirements for investigation of an analgesic. The hypothesis that vitamin B12 possesses painkilling properties must therefore be questioned, especially as no anti-nociceptive effect is reported in animal experiments.

Analgesics↗

[Cardiovascular effects of elliptinium. The mechanism of action].

The effects of elliptinium were studied: Firstly, in the dog, in comparison with the effects of histamine, on heart rate and arterial blood pressure. Secondly, in guinea-pig isolated atria. When smaller doses were used (0.375; 0.75; 1.5 mg/kg) elliptinium only induced variations of heart rate. With the dose of 3 mg/kg hypotension and tachycardia appeared. The time-course of these effects was different from that of histamine (5 micrograms/kg): later onset and longer duration. Elliptinium was inactive in isolated guinea-pig atria, as observed in tracheal or digestive isolated smooth muscle. Thus, the cardiovascular activity of this antitumoral agent seems to implicate an indirect mechanism of action. This result is in accordance with the previous results obtained on bronchopulmonary system.

Alkaloids↗

[Bepridil: hemodynamic and coronary effects on normal and/or ischemic myocardium in dogs (author's transl)].

1. The effects of bepridil, certain properties of which suggest antagonism of calcium flux, were studied: 1.1. On arterial blood pressure and heart rate in unanesthetized dogs. 1.2. On coronary and systemic hemodynamics in anesthetized dogs. 1.3. On regional blood flow (R.B.F.) in the myocardium of anesthetized dogs either normal or experimentally ischemic from temporary and/or permanent coronary occlusion. 2. Bepridil in unanesthetised dogs does not cause any significant change in heart rate or systolic blood pressure. Both the mean and diastolic blood pressures increase at the end of the observation period 20 minutes after the second injection. 3. In contrast, bepridil in anesthetized dogs induces a fall in peripheral resistance together with a drop in arterial blood pressure without any alteration in cardiac output. Both heart rate and contractile force are decreased while coronary flow is increased. 4. In models of localized transitory myocardial ischemia, bepridil (1 mg . kg-1 I.V.) induces a general increase in absolute R.B.F., particularly causing a favourable redistribution of coronary blood to the endocardium in ischemic areas, as evidenced by the improved endocardium/epicardium irrigation ratio. These favourable effects disappear when the dose of bepridil (3 mg . kg-1) used in this a preparation induces a marked drop in blood pressure and consequently a fall in coronary perfusion. 5. In models of localized permanent myocardial ischemia, bepridil has no effects either on R.B.F. in healthy or ischemic areas, or on the endocardium/epicardium irrigation ratios in these two types of areas.

Animals↗